Arrowhead Pharmaceuticals to Participate in Upcoming May 2022 Conferences
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will participate in several upcoming conferences in May 2022. Events include TIDES USA 2022 from May 9-12, where Michael Lawler will discuss scale-up manufacturing. At the American Thoracic Society Conference from May 13-18, David Kasahara will present on RNAi delivery platforms targeting lung inflammation. Arrowhead will also participate in the BofA Securities Healthcare Conference and the RBC Capital Markets Healthcare Conference on May 12 and 17, respectively, both featuring Christopher Anzalone. Further details are available on their website.
- None.
- None.
Title: Arrowhead’s Approach to Oligonucleotide Scale-Up Manufacturing
Presenter:
2022
Title: Silencing RAGE Expression with a Lung-Targeted RNAi Trigger Delivery Platform Suppresses Pulmonary Allergic Inflammation
Presenter:
Title: Silencing Muc5ac Expression with a Lung-Targeted RNAi Trigger Prevents Allergen-Induced Mucoobstruction and Airway Hyperresponsiveness
Presenter:
Type: Fireside chat presentation
Presenter:
2022
Type: Fireside chat presentation
Presenter:
Type: Fireside chat presentation
Presenter:
A copy of the presentation materials and webcast links may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.
About
For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” or “continue” are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005289/en/
626-304-3400
ir@arrowheadpharma.com
Investors:
212-915-2578
britchie@lifesciadvisors.com
www.lifesciadvisors.com
Media:
646-751-4361
jo@lifescicomms.com
www.lifescicommunications.com
Source:
FAQ
What events will Arrowhead Pharmaceuticals participate in during May 2022?
Who will present at the TIDES USA 2022 event for Arrowhead Pharmaceuticals?
What topics will be covered by David Kasahara at the ATS Conference?
When will Arrowhead Pharmaceuticals present at the BofA Securities Healthcare Conference?
What is the stock symbol for Arrowhead Pharmaceuticals?
